Change of Director's Interest Notice - Robert Proulx
Released
Released
Announcement PDF
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information
and documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity
IMAGION BIOSYSTEMS LIMITED
ABN
42 616 305 027
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for
the director for the purposes of section 205G of the Corporations Act.
Name of Director
Robert PROULX
Date of last notice
11 September 2020
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should
be disclosed in this part.
Direct or indirect interest
Direct
Nature of indirect interest
(including registered holder)
N/A
Note: Provide details of the circumstances giving rise to the relevant
interest.
Date of change
22 October 2020
No. of securities held prior to change
i) 3,487,000 Shares
ii) 7,500,000 Performance Rights
iii) 176,250 Listed Options (exercisable at
$0.05 expiring on 26 November 2021)
iv) 282,000 Listed Options (exercisable at
$0.03, expiring on 28 April 2023)
v) 2,000,000 Unlisted Performance Options
(exercisable at $0.028, vesting on 1 May
2021, expiring 1 May 2026)
vi) 2,000,000 Unlisted Performance Options
(exercisable at $0.028, vesting on 1 May
2022, expiring 1 May 2027)
vii) 2,000,000 Unlisted Performance Options
(exercisable at $0.028, vesting on 1 May
2023, expiring 1 May 2028)
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Appendix 3Y
Change of Director’s Interest Notice
Class
i) Fully Paid Ordinary Shares (Shares)
ii) Performance Rights
iii) Listed Options (exercisable at $0.05
expiring on 26 November 2021)
iv) Listed Options (exercisable at $0.03,
expiring on 28 April 2023)
v) Unlisted
Performance
Options
(exercisable at $0.028, vesting on 1 May
2021, expiring 1 May 2026)
vi) Unlisted
Performance
Options
(exercisable at $0.028, vesting on 1 May
2022, expiring 1 May 2027)
vii) Unlisted
Performance
Options
(exercisable at $0.028, vesting on 1 May
2023, expiring 1 May 2028)
Number acquired
i) 2,500,000 Shares
ii) Nil Performance Rights
iii) Nil Listed Options (exercisable at $0.05
expiring on 26 November 2021)
iv) Nil Listed Options (exercisable at $0.03,
expiring on 28 April 2023)
v) Nil Unlisted Performance Options
(exercisable at $0.028, vesting on 1 May
2021, expiring 1 May 2026)
vi) Nil Unlisted Performance Options
(exercisable at $0.028, vesting on 1 May
2022, expiring 1 May 2027)
vii) Nil Unlisted Performance Options
(exercisable at $0.028, vesting on 1 May
2023, expiring 1 May 2028)
Number disposed
2,500,000 Performance Rights
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Appendix 3Y
Change of Director’s Interest Notice
Value/Consideration
Note: If consideration is non-cash, provide details and estimated
valuation
No. of securities held after change
Nature of change
Example: on-market trade, off-market trade, exercise of options,
issue of securities under dividend reinvestment plan, participation in
buy-back
i)
ii)
Nil per Share
N/A Consideration for Performance
Rights
iii) N/A consideration for Listed Options
(exercisable at $0.05 expiring on 26
November 2021)
iv) N/A Consideration for Listed Options
(exercisable at $0.03, expiring on 28 April
2023)
v) N/A
Consideration
for
Unlisted
Performance Options (exercisable at
$0.028, vesting on 1 May 2021, expiring 1
May 2026)
vi) N/A
Consideration
for
Unlisted
Performance Options (exercisable at
$0.028, vesting on 1 May 2022, expiring 1
May 2027)
vii) N/A
Consideration
for
Unlisted
Performance Options (exercisable at
$0.028, vesting on 1 May 2023, expiring 1
May 2028)
i) 5,987,000 Shares
ii) 5,000,000 Performance Rights
iii) 176,250 Listed Options (exercisable at
$0.05 expiring on 26 November 2021)
iv) 282,000 Listed Options (exercisable at
$0.03, expiring on 28 April 2023)
v) 2,000,000 Unlisted Performance Options
(exercisable at $0.028, vesting on 1 May
2021, expiring 1 May 2026)
vi) 2,000,000 Unlisted Performance Options
(exercisable at $0.028, vesting on 1 May
2022, expiring 1 May 2027)
vii) 2,000,000 Unlisted Performance Options
(exercisable at $0.028, vesting on 1 May
2023, expiring 1 May 2028)
Shares were issued as the result of vesting of
Performance Rights.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should
be disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
(if issued securities)
Date of change
N/A
No. and class of securities to which interest related prior to change
N/A
N/A
Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 3
N/A
Appendix 3Y
Change of Director’s Interest Notice
Interest disposed
N/A
Value/Consideration
N/A
Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change
N/A
Part 3 – +Closed period
Were the interests in the securities or contracts detailed above traded
during a +closed period where prior written clearance was required?
If so, was prior written clearance provided to allow the trade to
proceed during this period?
No
If prior written clearance was provided, on what date was this
provided?
N/A
N/A
+ See chapter 19 for defined terms.
Appendix 3Y Page 4
01/01/2011
Share your feedback
Discover